🔴 Xenetic Biosciences is trading 7.1% down in pre-market with no clear immediate catalyst

Xenetic Biosciences is trading 7.1% lower at $2.34, with no clear immediate catalyst identified.

• No new company-specific announcement was identified for September 24, 2026.
• The latest major development remains the September 16 all-stock Santersus merger, which would leave existing shareholders with approximately 15% of the combined company.
• Broader markets are weaker, while biotech is higher.